Stock Market Watch

Hologic – MammoSite therapy delivers targeted radiation

by ·



Hologic, Inc. (NASDAQ:HOLX). Last Market Price: 14.22, Change: -0.01, % Change: (-0.07%). Shares trade in the range of 13.90 – 14.47 dollars. It has a market capitalization of 3.73B dollars, making it a Mid Cap Stock and has 262.14M outstanding shares. The company has a beta of 1.16, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.04. It operates in Healthcare sector and belongs to Medical Equipment and Supplies industry. Percentage shares held by institutional investors is 93%. The company has a 52 week high of $ 23.24 and a 52 week low of $ 13.90. Average volumes of shares traded daily are 1,810,000. Volume traded in the last session was at 1,500,000, 0.83 times the average volume.

  • MammoSite therapy delivers targeted radiation – Full course of radiation to be delivered in just five days, limiting radiation exposure to normal, healthy tissue.
  • Peter Beitsch, M.D., FACS, Dallas Breast Center in Texas and lead author of the study states:, “The ASBS MammoSite Registry has contributed to the acceptance of Accelerated Partial Breast Irradiation (APBI) across this country and the world by the reassuring long-term data on local control, lack of risk of regional recurrence in the era of the sentinel node biopsy, and the comparable long-term survival after whole breast irradiation.”

For Q2 (Jun ’11), It had a Net profit margin of 8.02%, an Operating margin of 16.39%. Other Key stats and ratios are : Return on average assets of 2.47%, Return on average equity of 5.04%. The organization has an employee strength of 4,220

Consensus Recommendation is a Outperform.


Estimate for sales for the Year Ending Sep-11 show a mean of 1,780.11 million dollars, an estimate high of 1,789.39 million dollars and an estimate low of 1,775.00 million dollars. A year ago the figures stood at 1,749.79 million dollars.

Estimate for sales for the Year Ending Sep-12 show a mean of 1,907.63 million dollars, an estimate high of 1,985.15 million dollars and an estimate low of 1,807.00 million dollars. A year ago the figures stood at 1,828.05 million dollars.

Estimate for EPS for the Year Ending Sep-11 show a mean of 1.25 dollars, an estimate high of 1.27 dollars and an estimate low of 1.24 dollars. A year ago the figures stood at 1.28 dollars.

Estimate for EPS for the Year Ending Sep-12 show a mean of 1.40 dollars, an estimate high of 1.54 dollars and an estimate low of 1.34 dollars. A year ago the figures stood at 1.39 dollars.

Sales for Quarter Ending Jun-11 was estimated at 446.67 million dollars, however the actual sales figure stood at 451.08 million dollars, 4.41 million dollars more than estimates.

Sales for Quarter Ending Mar-11 was estimated at 433.16 million dollars, however the actual sales figure stood at 438.65 million dollars, 5.49 million dollars more than estimates.

edliston
Post Written By: Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.


Tags:

Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...